search
Back to results

Acoart SCB SFA: Sirolimus Coated Balloon Catheter in the Treatment of Femoropopliteal Artery Stenosis

Primary Purpose

Peripheral Artery Disease

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Sirolimus-eluting balloon catheter
Paclitaxel-eluting balloon catheter
Sponsored by
Acotec Scientific Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Artery Disease focused on measuring Drug eluting balloon catheter, Peripheral Artery Disease

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥18 years old and ≤80 years old
  • Had lower extremity arterial occlusive diseases, and Rutherford classification is 2-5
  • SFA and/or popliteal artery had severe stenosis (stenosis degree ≥70%) or occlusion.
  • The length of target lesion less than 20 cm
  • Subject (or legal guardian) understands the study requirements and procedures and provides written Informed Consent before any study tests or procedures are performed

Exclusion Criteria:

  • The plasma creatinine level is higher than 150 umol/L
  • Thrombolysis or thrombectomy is required
  • There are more than 2 lesion need to treat in the target vessel.
  • The patient had underwent lower-limb arterial surgery or thrombolysis on the target limb within 6 weeks.
  • The target lesion had residual stenosis>30% or flow-limit dissection after pre-dilatation.
  • The patient had outflow less than 1 vessel
  • The lesion located in a stent.
  • Patient has a known allergy to aspirin, clopidogrel, heparin, paclitaxel, sirolimus or contrast medium that cannot be adequately pre-medicated.
  • Women who are pregnant or breast-feeding.
  • The subjects have participated in other drug property studies or device studies that have not yet completed the main end point.
  • Patient has life expectancy of less than 12 months.
  • The investigator think the patient is not suitable for participation in the clinical trial.

Sites / Locations

  • Chinese PLA General HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Sirolimus-eluting balloon angioplasty

Paclitaxel-eluting balloon angioplasty

Arm Description

Using Sirolimus Coated Balloon Catheter in the treatment of stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery

Using Paclitaxel Coated Balloon Catheter in the treatment of stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery

Outcomes

Primary Outcome Measures

The primary patency rate of target lesion at 12 months post-procedure
Defined as freedom from clinically driven target lesion revascularization (CD-TLR) and binary restenosis (restenosis defined as duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≥2.4)

Secondary Outcome Measures

Rate of device success
Defined as successful delivery, balloon inflation, deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP)
Rate of clinically driven target lesion revascularization (CD-TLR) at 12 months post-procedure
Defined as any reintervention at the target lesion due to symptoms or the following index: drop of ABI >20% or ABI >0.15 compared to the post-procedure ABI during 12 months post-procedure
The change of Rutherford class from baseline
Defined as change in target limb Rutherford class from baseline to 12 months
The change of ankle-brachial index (ABI) from baseline
Defined as change of target limb ABI from baseline to 12 months
Rate of composite safety endpoint
Defined a composite rate of device-related or procedure-related death, major target limb amputation (above-the-ankle amputation), clinically driven target lesion revascularization (CD-TLR) or target lesion thrombotic events through 30 days post- procedure

Full Information

First Posted
July 21, 2021
Last Updated
October 16, 2023
Sponsor
Acotec Scientific Co., Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT04982367
Brief Title
Acoart SCB SFA: Sirolimus Coated Balloon Catheter in the Treatment of Femoropopliteal Artery Stenosis
Official Title
A Prospective, Multicenter, Randomized Controlled Trial Comparing the Efficacy and Safety Between Sirolimus Coated Balloon Catheter and Paclitaxel Coated Balloon Catheter in the Treatment of Femoropopliteal Artery Stenosis.
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 8, 2021 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
July 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Acotec Scientific Co., Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
A prospective randomized trial designed to compare the efficacy and safety of Sirolimus coated balloon (SCB) versus paclitaxel coated balloon (DCB) in the treatment of femoropopliteal artery stenosis

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Artery Disease
Keywords
Drug eluting balloon catheter, Peripheral Artery Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
166 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Sirolimus-eluting balloon angioplasty
Arm Type
Experimental
Arm Description
Using Sirolimus Coated Balloon Catheter in the treatment of stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
Arm Title
Paclitaxel-eluting balloon angioplasty
Arm Type
Active Comparator
Arm Description
Using Paclitaxel Coated Balloon Catheter in the treatment of stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
Intervention Type
Device
Intervention Name(s)
Sirolimus-eluting balloon catheter
Other Intervention Name(s)
Sirolimus coated balloon catheter
Intervention Description
Sirolimus-eluting balloon catheter designed and produced by Acotec
Intervention Type
Device
Intervention Name(s)
Paclitaxel-eluting balloon catheter
Other Intervention Name(s)
Paclitaxel coated balloon catheter
Intervention Description
Paclitaxel-eluting balloon catheter (trade name:DHALIA)
Primary Outcome Measure Information:
Title
The primary patency rate of target lesion at 12 months post-procedure
Description
Defined as freedom from clinically driven target lesion revascularization (CD-TLR) and binary restenosis (restenosis defined as duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≥2.4)
Time Frame
12 months post-procedure
Secondary Outcome Measure Information:
Title
Rate of device success
Description
Defined as successful delivery, balloon inflation, deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP)
Time Frame
immediate post-procedure
Title
Rate of clinically driven target lesion revascularization (CD-TLR) at 12 months post-procedure
Description
Defined as any reintervention at the target lesion due to symptoms or the following index: drop of ABI >20% or ABI >0.15 compared to the post-procedure ABI during 12 months post-procedure
Time Frame
12 months post-procedure
Title
The change of Rutherford class from baseline
Description
Defined as change in target limb Rutherford class from baseline to 12 months
Time Frame
12 months post-procedure
Title
The change of ankle-brachial index (ABI) from baseline
Description
Defined as change of target limb ABI from baseline to 12 months
Time Frame
12 months post-procedure
Title
Rate of composite safety endpoint
Description
Defined a composite rate of device-related or procedure-related death, major target limb amputation (above-the-ankle amputation), clinically driven target lesion revascularization (CD-TLR) or target lesion thrombotic events through 30 days post- procedure
Time Frame
30 days post-procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥18 years old and ≤80 years old Had lower extremity arterial occlusive diseases, and Rutherford classification is 2-5 SFA and/or popliteal artery had severe stenosis (stenosis degree ≥70%) or occlusion. The length of target lesion less than 20 cm Subject (or legal guardian) understands the study requirements and procedures and provides written Informed Consent before any study tests or procedures are performed Exclusion Criteria: The plasma creatinine level is higher than 150 umol/L Thrombolysis or thrombectomy is required There are more than 2 lesion need to treat in the target vessel. The patient had underwent lower-limb arterial surgery or thrombolysis on the target limb within 6 weeks. The target lesion had residual stenosis>30% or flow-limit dissection after pre-dilatation. The patient had outflow less than 1 vessel The lesion located in a stent. Patient has a known allergy to aspirin, clopidogrel, heparin, paclitaxel, sirolimus or contrast medium that cannot be adequately pre-medicated. Women who are pregnant or breast-feeding. The subjects have participated in other drug property studies or device studies that have not yet completed the main end point. Patient has life expectancy of less than 12 months. The investigator think the patient is not suitable for participation in the clinical trial.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Guo Wei, MD
Phone
010-66887329
Email
pla301dml@vip.sina.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guo Wei, MD
Organizational Affiliation
Chinese PLA General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chinese PLA General Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100039
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wei Guo, MD
Phone
010-66887329
Email
pla301dml@vip.sina.com

12. IPD Sharing Statement

Learn more about this trial

Acoart SCB SFA: Sirolimus Coated Balloon Catheter in the Treatment of Femoropopliteal Artery Stenosis

We'll reach out to this number within 24 hrs